Welcome to our dedicated page for Codexis SEC filings (Ticker: CDXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Codexis, Inc. (CDXS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Codexis is listed on The Nasdaq Global Select Market, and its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934, as reflected in its Form 8-K filings. These filings give investors insight into how Codexis reports its financial condition, strategic actions and material events related to its enzymatic solutions for therapeutics manufacturing and its ECO Synthesis® / ECO Synthesis™ platform.
Among the key documents available are Form 10-K annual reports and Form 10-Q quarterly reports, which typically contain detailed discussions of Codexis’s business, risk factors, financial statements and management’s analysis of results. For a company focused on enzyme technologies and oligonucleotide manufacturing, these filings can shed light on revenue contributions from its Pharma Biocatalysis business, investments in research and development for platforms such as CodeEvolver® and ECO Synthesis, and the financial impact of collaborations and licensing arrangements.
Codexis also files Form 8-K current reports to disclose material events. For example, an 8-K dated November 6, 2025 reports quarterly financial results and describes a workforce reduction aligned with an enhanced strategic focus on the ECO Synthesis platform, as well as executive leadership changes. Another 8-K dated August 13, 2025 announces financial results for the quarter ended June 30, 2025. These current reports help investors track significant developments between periodic filings.
On this page, users can also review Form 4 insider transaction reports and other relevant filings, where available, to understand equity awards and trading activity by directors and officers. Stock Titan enhances access to these documents with AI-powered summaries that explain key points from lengthy filings, highlight important sections in 10-K and 10-Q reports, and clarify the implications of 8-K disclosures. Real-time updates from EDGAR ensure that new Codexis filings, including those related to its enzyme-based manufacturing initiatives and organizational changes, are reflected promptly for further review and analysis.
Codexis, Inc. (CDXS) reported an equity award to its President and CEO, Alison Moore, on Form 4. On 11/13/2025 she received 85,000 shares of common stock in the form of restricted stock units, at a stated price of $0. These units vest in three equal annual installments on each anniversary of the grant date, provided she remains employed.
On the same date she was also granted a stock option for 500,000 shares of common stock at an exercise price of $1.63 per share, expiring on 11/13/2035. The option vests as to 25% of the shares on the first anniversary of the grant date and 1/48th of the original total each month thereafter, conditioned on continued employment. Following these transactions, she beneficially owns 254,332 shares, including 145,208 restricted stock units.
Codexis, Inc. (CDXS) chief scientific officer reports equity holdings in a beneficial ownership statement dated 11/07/2025. The officer directly owns 143,460 shares of Codexis common stock, including 53,266 restricted stock units that each convert into one share upon vesting. In addition, the officer holds multiple stock options covering shares of common stock with exercise prices ranging from $3.05 to $26.16 and expirations between 2030 and 2035. Some options are already fully vested and exercisable, while others vest over time based on specified schedules tied to dates from 2021 through 2026.
Codexis (CDXS): Opaleye Management Inc., as reporting person, disclosed open‑market sales of Codexis common stock on 11/12/2025. Transactions included 890,000 shares at $1.9372 and 165,000 shares at $1.962 through Opaleye, L.P., plus 27,459 shares at $1.9372 via a separately managed account. The prices are weighted averages; the shares were sold in multiple trades within disclosed ranges.
Following the reported transactions, beneficial ownership reported as indirect included 10,453,318 shares by Opaleye, L.P. and 196,012 shares by the managed account. The pricing footnotes state sales occurred across ranges of $1.9005–$1.9905 and $1.935–$2.0035, with full trade details available upon request.
Codexis (CDXS)
Codexis, Inc. (CDXS) reported an insider open‑market purchase. Director Stephen G. Dilly bought 50,000 shares of common stock on 11/11/2025 at a weighted average price of $1.8473, executed in multiple trades ranging from $1.7550 to $1.90.
After this transaction, he beneficially owns 727,053 shares, held directly. This total includes 2,000 shares acquired under the Employee Stock Purchase Plan on May 10, 2025 and 2,000 shares acquired on Nov 10, 2025.
Opaleye Management Inc., a director of Codexis (CDXS), reported open‑market sales of common stock. Transactions occurred on 11/07/2025, 11/10/2025, and 11/11/2025 at weighted average prices of $1.6968, $1.7347, and $1.7994, respectively.
Reported sale sizes included 296,682 and 10,000 shares on 11/07/2025; 205,000 and 3,318 shares on 11/10/2025; and 535,000 and 13,211 shares on 11/11/2025. Following these transactions, beneficial ownership was 11,508,318 shares indirectly through Opaleye, L.P., and 223,461 shares indirectly through a managed account.
Codexis (CDXS) filed its Q3 2025 10‑Q, reporting revenue of $8.6 million and a net loss of $19.6 million (basic and diluted loss per share $0.22). Product revenue was $6.8 million and research and development revenue was $1.8 million. Product gross margin was 64%.
Cash and cash equivalents were $25.4 million with short‑term investments of $33.4 million, totaling $58.7 million as of September 30, 2025. Long‑term debt was $39.7 million, primarily the Innovatus term loan. Operating cash use was $39.5 million for the nine‑month period; financing inflows included $17.3 million of common stock sales under the Cantor at‑the‑market agreement.
Subsequent events: in October 2025, Codexis entered an enzyme supply assurance agreement with Merck that provides a one‑time $37.8 million payment expected in Q4 2025. On November 6, 2025, the company announced a workforce reduction of approximately 24%, with an estimated $3.5 million expense expected in Q4 2025. Shares outstanding were 90,324,383 as of November 3, 2025.
Codexis, Inc. announced organizational and leadership changes. The company is implementing a workforce reduction of approximately 24% to align with its focus on the ECO Synthesis platform. It expects to recognize about $3.5 million of related expenses in the fourth quarter of 2025, paid primarily in the same period, with the reduction substantially completed by January 2026.
The Board appointed Alison Moore, Ph.D., as President and Chief Executive Officer and as a Class III director, effective November 7, 2025. Her compensation includes a $650,000 base salary, a target annual bonus of 75% of salary, 85,000 RSUs vesting over three years, and 500,000 stock options vesting over four years. Stephen Dilly will continue as Chair of the Board with annual cash fees of $110,000. Kevin Norrett entered into a separation and consulting agreement and will provide transitional services through November 6, 2026, and will receive a bonus equal to 100% of his target bonus.
Codexis (CDXS) reported an insider transaction by its Chief Financial Officer, Georgia Erbez. On 10/13/2025, she sold 6,239 shares of common stock at $2.505 per share. The filing notes the sale was made solely to satisfy tax or other government withholding obligations tied to the vesting of Restricted Stock Units.
Following the transaction, Erbez beneficially owned 70,636 shares directly, which includes 33,333 RSUs. The transaction code was listed as S, indicating a sale.
Codexis (CDXS) filed a Form 4 reporting that Chief Technical Officer Alison Moore sold 6,239 shares of common stock on 10/13/2025 at $2.5051 per share. The filing states the sale was made solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units.
Following the transaction, Alison Moore beneficially owns 169,332 shares, which includes 33,333 restricted stock units. Ownership is reported as direct, and the filing was made by one reporting person.
FAQ
What is the current stock price of Codexis (CDXS)?
What is the market cap of Codexis (CDXS)?
